Latest news

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency

22 Aug 2019

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA

Mundipharma announces exclusive license and supply agreement with Prestige Biopharma for Tuznue® (HD201)

2 Jul 2019

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Invokana® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis

11 Jun 2019

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Mundipharma announces exclusive outsourcing distribution agreement with Egis Pharmaceuticals for Pelmeg▼® in Central and Eastern Europe

13 May 2019

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

16 Apr 2019

EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Mountain rescue study launches to investigate use of Penthrox® (methoxyflurane) for trauma-related pain in hostile environments

27 Mar 2019

FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY

Mundipharma Announces Launch of INVOKANA® and VOKANAMET® in Norway for the Treatment of Type 2 Diabetes as Part of Exclusive Distribution Agreement with Janssen

19 Mar 2019

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

Mundipharma opens its doors to local schools to inspire the next generation of scientists

13 Mar 2019

FOR LOCAL MEDIA ONLY

Mundipharma wins 1st ever PLG deal of the year award for acquisition of Cinfa Biotech

26 Feb 2019

Mundipharma appoints Patrice Grand as European Director of Corporate Communications

19 Feb 2019

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Mundipharma launches Pelmeg®▼(pegfilgrastim) biosimilar in Europe

7 Feb 2019

PAN-EU RELEASE FOR DISTRIBUTION TO MEDICAL AND BUSINESS OUTLETS ONLY

Mundipharma announces Marco Cerato as Senior Vice President Business Development and Strategic Partnerships

30 Nov 2018

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

European Commission approves Pelmeg▼® (pegfilgrastim) as a biosimilar treatment to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy

23 Nov 2018

FOR EUROPEAN MEDICAL MEDIA ONLY

Mundipharma announces Chief Financial Officer

19 Nov 2018

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

flutiform® receives a positive opinion in Europe for the Treatment of Children with Asthma

7 Nov 2018

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA

New guidance from ADA and EASD recommends use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for patients with type 2 diabetes

16 Oct 2018

FOR EU MEDICAL MEDIA ONLY, NOT FOR DISTRIBUTION TO US MEDIA

Mundipharma strengthens position as a leader in biosimilars with acquisition of development company Cinfa Biotech

10 Oct 2018

FOR BUSINESS AND TRADE MEDIA ONLY

Mundipharma announces Philippe Bastide as Head of Biosimilars

5 Oct 2018

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

flutiform® k-haler®, a Novel Treatment for Adolescents and Adults with Asthma, now Available in Europe

10 Sep 2018

FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA

European Commission expands labelling for INVOKANA® and VOKANAMET® to include positive data on cardiovascular and renal outcomes

7 Sep 2018

FOR EUROPEAN BUSINESS/TRADE MEDIA ONLY

Innovative pharmaceutical pricing agreements preferable to discounts, according to new European payer survey

21 Aug 2018

FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY

Picture of Will Dunlop author of article pharmaceutical market access in Europe

Pharmaceutical market access in Europe, by Will Dunlop

16 Aug 2018

EUROPEAN TRADE/MEDICAL MEDIA ONLY

The CHMP issues positive opinion to expand INVOKANA® and VOKANAMET® labels to include positive data on cardiovascular and renal outcomes

2 Aug 2018

INFORMATION FOR EUROPEAN MEDICAL/TRADE ONLY

Mundipharma International welcomes positive phase III efficacy findings for Invokana® (canagliflozin) in type 2 diabetes patients with chronic kidney disease

20 Jul 2018

INFORMATION FOR EUROPEAN MEDICAL/TRADE MEDIA ONLY

What the patient access experts are saying

18 Jun 2018

BY WILL DUNLOP, HEAD OF MARKET ACCESS, MUNDIPHARMA INTERNATIONAL

1 2